Medicare AdvantageCoverageMedium impact
MA06.036, Protein Biomarkers for the Diagnosis and Cancer Risk Assessment of Prostate Cancer
Independence Blue Cross·Urology, Oncology·Medical Policy
Effective date
Jan 27, 2025
We identified it
Jun 19, 2026
Summary
MA06.036 is a new Medicare Advantage policy establishing coverage criteria for protein biomarkers used in prostate cancer diagnosis and risk assessment. The policy becomes effective 01/27/2025 and will require billing teams to understand covered biomarker tests, documentation requirements, and any prior authorization mandates to ensure proper claim submission and reimbursement.
Action Required
By 01/27/2025: Billing team must obtain and review the complete MA06.036 policy text from the provided URL to identify: (1) specific CPT/HCPCS codes for covered protein biomarker tests, (2) prior authorization requirements, (3) medical necessity documentation standards, and (4) any age or clinical criteria restrictions. Update billing system rules and provider documentation templates accordingly. Urology and oncology providers must be notified of coverage criteria. Claims submitted without adherence to this new policy will risk denial. Recommend scheduling a policy review meeting with clinical and billing staff before the effective date.